Proactive Investors - Run By Investors For Investors

Small Cap Wrap - Science in Sport; Tekcapital and Maestrano

Small Cap Wrap - Science in Sport; Tekcapital and Maestrano

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

922*

Total number of AIM Companies trading:

851*

*as at close of business  09 November 2018

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):

138*

Total number of Standard List Companies trading:

120*

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

88*

Total number of NEX Growth Market Companies trading:

86*               

*as at close of business 09 November 2018                     

*A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity                        

Dish of the day

No Joiners Today

Off the menu      

No Leavers Today

             

Banquet Buffet

Cambridge Cognition  (LON:COG) 114p £22.4m

The specialist in neuroscience technology to assess brain health, today announced it has won a significant new clinical trial contract, which is the largest in a series of recently signed electronic clinical outcomes assessment (eCOA) trials.

The contract is worth over $0.75m with a new client for the Company, a specialty pharmaceutical developer, over a one-year period. It is the largest of a number of eCOA contracts won since Cambridge Cognition decided to increase the value of its software service by expanding the capabilities of its CANTAB Connect platform. The technology now enables the assessment of multiple outcomes, in addition to cognitive measures, on a single platform.

FY2018E revs of £6.9m and EBITDA of -£0.4m

AB Dynamics (LON:ABDP) 1,425p £271m

FYAug18 results from the designer, manufacturer and supplier of advanced testing systems and measurement products to the global automotive industry.

Revenue increased 51% to £37.05m (FY17: £24.57m)

Reported PBT increased 78% to £7.95m (FY17: £4.47m)

PBT increased 45% to £8.61m (FY17: £5.94m)

Diluted EPS increased 70% to 35.03p (FY17: 20.56p)

Proposed final dividend increased 10% to 2.20p per ordinary share (FY17: 2.00p)

Strong balance sheet with net cash of £15.94m as at 31 Aug 2018

Very strong outlook statement although hints at increasing cost base to accommodate growth which may constrain margins.

Falanx  (LON:FLX) 3.12p £7.99m

HYSep18 results from the cybersecurity and intelligence provider .

Group revenues increased 51% to £2.2m (2017: £1.4m) and gross margin increased to 36% (2017: 27%). 198% increase in Cyber division revenues to £1.4m (2017: £0.47m) Underlying EBITDA £0.71m loss (2017: £0.85m loss),

Recurring revenues remain strong and grew by 41% to £1.2m 

Cash of £69k.

“The SolarWinds opportunity is transformational for Falanx both in terms of customer capture and potential financial returns.  Over the next few months, there will be a necessary expansion in the deployment of our resources to meet the expected increase in activity. Whilst revenues for the first half, although well ahead of the same period last year, have been slightly lower than our original internal expectations”.

We could see no forecasts.

Lighthouse Group (LON:LGT) 27.3p £33.8m

“The national financial advisory group, is pleased to announce that it has entered into a strategic relationship with Tavistock Investments plc.

Lighthouse currently advises clients with assets in excess of £5bn and on new investment and pension flows of circa £1bn p.a. The Strategic Agreement will enable Lighthouse and its advisers and clients to access Tavistock's investment solutions, including its capital protection fund products that are principally invested in iShares by BlackRock and guaranteed by Morgan Stanley, all managed to the client's agreed risk profile.”

Marshall Motor Holdings (LON:MMH) 156p £114m

“One of the UK's leading automotive retail groups, issues the following trading update in response to better than anticipated trading during Oct 2018 and a more positive outlook for the remainder of the current financial year.

As previously announced on 11 Oct 2018, the introduction of the new Worldwide Harmonised Light Vehicle Test Procedure  had a significant impact on the UK new vehicle market during Sept 2018 which was expected to continue for the remainder of the year. Whilst the resultant new car supply imbalance is continuing, growth in our used car volumes and margins given supply constraints in the new car market, combined with further revenue growth achieved in aftersales, has given us more confidence over the expected outcome for the year.  As a result, the Board now expects continuing underlying profit before tax for the year ending 31 Dec 2018 to be ahead of the Group's record results reported last year.”

FY2018E revs of £2,191m and EBITDA of £39.8m

Tekcapital (LON:TEK) 6.25p £3.51m 

“The UK intellectual property (IP) investment group focused on creating marketplace value from university technology, is pleased to announce that wholly owned portfolio company Lucyd ltd has launched an Affiliate and Reseller Program.

Lucyd Pte Ltd, the developer of an eShop for innovative spectacles, has launched a global affiliate and reseller program using the Leaddyno and Shareasale affiliate platforms. Lucyd has also introduced a reseller Intro Kit to provide initial stock and marketing materials for Lucyd products. As of today, seventy affiliates have already signed-up.

Interested parties are encouraged to sign up at Lucyd.leaddyno.com and contact [email protected] for assistance. Lucyd will regularly update the platforms with new collateral content, as well as publish a weekly affiliate newsletter.”

Craven House (LON:CRV) 3.30p £6.44m 

“Craven House announced its participation in a Public Offering for shares of LM Funding America, Inc.. The Company has acquired 640,000 common shares at a price of $2.40 per share for a total consideration of c.$1.5m. The Company's position represents 31.5% of the common shares in LMFA.

In the year to 31 Dec 2017, LM Funding America made a loss before income tax of $5.2m and had total assets of $2m.”

LM Funding America, Inc., together with its subsidiaries, is a technology-based specialty finance company that provides funding to non-profit community associations primarily located in the state of Florida.

Maestrano (LON:MNO) 9.12p £7m

The open cloud business integration platform with cross-app data synchronization, announces it has now successfully gone live with a platform for a major US based banking customer.

This Maestrano platform is used by Enterprises to assemble and serve integrated suites of Cloud applications with value-adding data analytics to drive engagement with their small and medium sized customers. Maestrano has been working with the US Bank for almost a year developing new digital services using the Maestrano platform which allow increased functionality for SMB users.

Science in Sport (LON:SIS) 61.5p £47.4m

The endurance sports nutrition company that develops, manufactures and markets sports nutrition products for elite athletes and sports enthusiasts, announced the proposed acquisition of PhD Nutrition Ltd ("PhD"), a premium, innovation-led protein brand for total consideration of £32m. Proposed £29m placing at 60p.

For the year ended 31 August 2018, PhD generated revenue of £20.8m and adjusted EBITDA of £2.8m.

"The acquisition of PhD is highly complementary, doubles the size of our business and accelerates our ambition to become a global leader in premium performance nutrition. It is a compelling combination that will deliver a wider product offering, including premium protein, provide broader consumer reach and greater international presence, and dovetails our respective strengths in retail and e-commerce channels.”

 

 

Hybridan LLP Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute  “independent investment research” for the purposes of the Financial Services Authority (FSA) rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers  and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons.  For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.  Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

 

Proactive Investors Limited Disclaimer

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

 

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use